Data on Waldenstrom Macroglobulinemia Reported by Researchers at Harvard Medical School (Optimizing Btk Inhibition In Waldenstro <euro> M Macroglobulinemia).

Researchers at Harvard Medical School have presented data on the treatment of Waldenstrom Macroglobulinemia (WM), a type of cancer. They propose a genomic-driven approach to selecting patients who are more likely to respond well to BTK inhibitors, a standard treatment for WM. The researchers also discuss strategies for managing the adverse effects of these inhibitors. Ongoing clinical trials are exploring different types of BTK inhibitors and combination therapies, showing promise for the future of WM treatment. [Extracted from the article]